RxDoctor Payments Data

Rani Karipineni, MD

Internal Medicine · Glen Burnie, MDNPI 1083648174

Payments from drug & device makers

$1,542in general payments, 2019–2025

Across 102 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$251
  • AstraZeneca$224
  • Lilly USA, LLC$170
  • Novo Nordisk$143
  • GSK$104
  • Amarin Pharma, Inc.$94
  • plus $557 from 14 others

What the payments were for

  • Food & beverage$1,46795%
  • Education$755%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,542 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$204,563
Medicare patients
484
Services billed
2,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin96$132,030
EliquisApixaban114$129,051
RybelsusSemaglutide41$91,804
OzempicSemaglutide49$88,631
Trelegy ElliptaFluticasone/Umeclidin/Vilanter80$72,594
MyrbetriqMirabegron46$38,094
XareltoRivaroxaban20$32,798
FarxigaDapagliflozin Propanediol25$29,578
TradjentaLinagliptin24$26,548
Tresiba Flextouch U-100Insulin Degludec27$17,524
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog45$16,061
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$13,755
CreonLipase/Protease/Amylase11$13,639
EntrestoSacubitril/Valsartan14$12,720
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$10,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$143$180,43590 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$79$167,713132 claims
PfizerEliquis$251$129,051114 claims
GSKTrelegy Ellipta, Anoro Ellipta$104$86,34993 claims
Astellas Pharma US IncMyrbetriq$75$38,09446 claims
Johnson & JohnsonXarelto$44$32,79820 claims
AstraZenecaFarxiga$224$29,57825 claims
AbbVieCreon$68$13,63911 claims
NovartisEntresto$75$12,72014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Glen Burnie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →